Home › Research › Mild cognitive impairment
Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data
Feride H. Frech, Gang Li, Timothy R. Juday, Yingjie Ding, Soeren Mattke, Ara S. Khachaturian, Aaron Seth Rosenberg, Colette Ndiba-Markey et al.. Journal of Managed Care & Specialty Pharmacy, 2025-07-24
Topic: Risk, prevention and care in population studies
< 0.0001) were significantly higher for the MCI cohort. The economic burden of MCI was more than double that for similar individuals without MCI or dementia. Timely diagnosis and intervention are key to delaying progression to AD and reducing associated costs.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Frech, F. H., Li, G., Juday, T. R., Ding, Y., Mattke, S., Khachaturian, A. S., et al. (2025). Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data. Journal of Managed Care & Specialty Pharmacy. https://doi.org/10.18553/jmcp.2025.31.8.782
Vancouver
Frech FH, Li G, Juday TR, Ding Y, Mattke S, Khachaturian AS, et al. Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data. Journal of Managed Care & Specialty Pharmacy. 2025. doi:10.18553/jmcp.2025.31.8.782. PMID: 40704847.
BibTeX
@article{frech2025-40704847,
author = {Frech, Feride H. and Li, Gang and Juday, Timothy R. and Ding, Yingjie and Mattke, Soeren and Khachaturian, Ara S. and Rosenberg, Aaron Seth and Ndiba-Markey, Colette and others},
title = {{Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data}},
journal = {Journal of Managed Care \& Specialty Pharmacy},
year = {2025},
doi = {10.18553/jmcp.2025.31.8.782},
pmid = {40704847},
url = {https://doi.org/10.18553/jmcp.2025.31.8.782}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- < 0.0001) were significantly higher for the MCI cohort.
- The economic burden of MCI was more than double that for similar individuals without MCI or dementia.
- Timely diagnosis and intervention are key to delaying progression to AD and reducing associated costs.
Why it matters
This retrospective cohort study found that the economic burden of mild cognitive impairment was more than double that for similar individuals without mild cognitive impairment or dementia. The authors state that timely diagnosis and intervention are key to delaying progression to Alzheimer's disease and reducing costs, but this is a cost study, not a treatment or cure.
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 45/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Managed Care & Specialty Pharmacy) |
| Journal's citation record | 0 / 4 | Journal of Managed Care & Specialty Pharmacy: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Harald Juergen Hampel: h-index 136 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40704847) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.18553/jmcp.2025.31.8.782
- PubMed: 40704847
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Related studies in Mild cognitive impairment
Also tagged “examination”
840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.